Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
71. |
ECCT/20/03/01 | GlycoShig3 A Phase 2a age descending study to investigate the safety and immunogenicity of the SF2a-TT15 synthetic carbohydrate-based conjugate vaccine against Shigella flexneri 2a in adult, children and infant target population in endemic countries. |
Principal Investigator(s) 1. Fredrick Kipyegon Sawe Site(s) in Kenya Kenya Medical Research Institute Walter Reed Project Kericho |
View |
72. |
ECCT/23/11/01 | MPZ-MAL-01 A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed with Uncomplicated Plasmodium falciparum Malaria |
Principal Investigator(s) 1. Lucas Otieno Tina Site(s) in Kenya 1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 2. AHERO CLINICAL TRIALS UNIT (Kisumu county) 3. Kenya Medical Research Institute(KEMRI):Siaya Clinical Research Annex (Siaya county) |
View |
73. |
ECCT/16/02/06 | A study of the safety and immune response of 2 doses of a new Shigella vaccine in Kenyan adults. A Phase 2a, observer blind, randomized, controlled, Single Center Study to evaluate the Safety, Reactogenicity and Immunogenicity of 2 doses of the GVGH 1790GAHB Vaccine against Shigella sonnei, administered intramuscularly in Adult Subjects from a country endemic for shigellosis [GVGH study H03_04TP] |
Principal Investigator(s) 1. Christina Wesonga Obiero Site(s) in Kenya Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme |
View |
74. |
ECCT/11/10/05 | A Phase 3, Open Label, Randomized, Comparative Study to Evaluate Azithromycin Plus Chloroquine and Sulfadoxine Plus Pyrimethamine Combinations for Intermittent Preventive Treatment of Falciparum Malaria Infection in Pregnant Women in Africa. WRAIR #1775, KEMRI SSC #1983 |
Principal Investigator(s) 1. Lucas Otieno Tina Site(s) in Kenya 1. KEMRI/WRP Kombewa (Kisumu county) |
View |
75. |
ECCT/20/05/01 | ChAdOx1 nCoV-19 trial A phase Ib/II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya |
Principal Investigator(s) 1. George Warimwe Site(s) in Kenya KEMRI-CGMRC |
View |